BLAINJECTIONINJECTABLEPriority Review
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
30/100
Mechanism of Action
deruxtecan-dlnk, is a Trop-2-directed antibody-drug conjugate. The antibody is a humanized anti-Trop2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to Trop-2 on cells, including tumor cells, datopotamab…
Indications (11)
metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)platinum-based chemotherapymetastatichormone receptor (HR)-positivehuman epidermal growth factor receptor 2 (HER2)-negative (IHC 0IHC 1+IHC 2+/ISH-) breast cancerchemotherapy for unresectablemetastatic diseaselung cancerbreast cancer